KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation and Depletion (2020 - 2024)

Recursion Pharmaceuticals' Depreciation and Depletion history spans 5 years, with the latest figure at $6.2 million for Q4 2024.

  • For Q4 2024, Depreciation and Depletion rose 47.62% year-over-year to $6.2 million; the TTM value through Dec 2024 reached $18.3 million, up 14.38%, while the annual FY2025 figure was $33.7 million, 84.15% up from the prior year.
  • Depreciation and Depletion reached $6.2 million in Q4 2024 per RXRX's latest filing, up from $4.0 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $6.2 million in Q4 2024 to a low of $1.0 million in Q1 2020.
  • Average Depreciation and Depletion over 5 years is $2.9 million, with a median of $2.8 million recorded in 2022.
  • Peak YoY movement for Depreciation and Depletion: surged 140.0% in 2021, then dropped 4.76% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $1.1 million in 2020, then skyrocketed by 127.27% to $2.5 million in 2021, then grew by 24.0% to $3.1 million in 2022, then surged by 35.48% to $4.2 million in 2023, then skyrocketed by 47.62% to $6.2 million in 2024.
  • Per Business Quant, the three most recent readings for RXRX's Depreciation and Depletion are $6.2 million (Q4 2024), $4.0 million (Q3 2024), and $4.1 million (Q2 2024).